Independent prognostic significance of day 21 cytogenetic findings in newly-diagnosed acute myeloid leukemia or refractory anemia with excess blasts

Marina Konopleva, Su Chun Cheng, Jorge E. Cortes, Kimberly J. Hayes, Sherry A. Pierce, Michael Andreeff, Francis J. Giles, Susan O'Brien, Hagop M. Kantarjian, Elihu H. Estey

Research output: Contribution to journalArticle

Abstract

Background and Objectives. We investigated whether cytogenetic findings (CG) on day 21 (D21) of the first course of chemotherapy predicted subsequent outcome in patients who presented with CG abnormalities. Design and Methods. D21 CG analysis was performed in 197 patients. Results. Nineteen percent of the patients had exclusively abnormal metaphases (AA), 31% had only normal metaphases (NN), 39% had normal and abnormal metaphases (AN), and 11% had insufficient metaphases (0/0) on D21. A complete response was achieved in 79% of patients with NN, 60% with AN, 27% of those with AA, and 32% of those with 0/0. Interpretations and Conclusions. Disease-free survival in CR was longest in patients who had ≥1 normal metaphase on D21, with this finding being independent of D21 marrow and initial CG results. D21 CG can be used in therapeutic decision-making.

Original languageEnglish (US)
Pages (from-to)733-736
Number of pages4
JournalHaematologica
Volume88
Issue number7
StatePublished - Jul 1 2003
Externally publishedYes

Fingerprint

Refractory Anemia with Excess of Blasts
Metaphase
Acute Myeloid Leukemia
Cytogenetics
Cytogenetic Analysis
Chromosome Aberrations
Disease-Free Survival
Decision Making
Bone Marrow
Drug Therapy

Keywords

  • AML
  • Day 21 cytogenetics

ASJC Scopus subject areas

  • Hematology

Cite this

Independent prognostic significance of day 21 cytogenetic findings in newly-diagnosed acute myeloid leukemia or refractory anemia with excess blasts. / Konopleva, Marina; Cheng, Su Chun; Cortes, Jorge E.; Hayes, Kimberly J.; Pierce, Sherry A.; Andreeff, Michael; Giles, Francis J.; O'Brien, Susan; Kantarjian, Hagop M.; Estey, Elihu H.

In: Haematologica, Vol. 88, No. 7, 01.07.2003, p. 733-736.

Research output: Contribution to journalArticle

Konopleva, M, Cheng, SC, Cortes, JE, Hayes, KJ, Pierce, SA, Andreeff, M, Giles, FJ, O'Brien, S, Kantarjian, HM & Estey, EH 2003, 'Independent prognostic significance of day 21 cytogenetic findings in newly-diagnosed acute myeloid leukemia or refractory anemia with excess blasts', Haematologica, vol. 88, no. 7, pp. 733-736.
Konopleva, Marina ; Cheng, Su Chun ; Cortes, Jorge E. ; Hayes, Kimberly J. ; Pierce, Sherry A. ; Andreeff, Michael ; Giles, Francis J. ; O'Brien, Susan ; Kantarjian, Hagop M. ; Estey, Elihu H. / Independent prognostic significance of day 21 cytogenetic findings in newly-diagnosed acute myeloid leukemia or refractory anemia with excess blasts. In: Haematologica. 2003 ; Vol. 88, No. 7. pp. 733-736.
@article{3f9a42151d3842bf8585c1d7ee096731,
title = "Independent prognostic significance of day 21 cytogenetic findings in newly-diagnosed acute myeloid leukemia or refractory anemia with excess blasts",
abstract = "Background and Objectives. We investigated whether cytogenetic findings (CG) on day 21 (D21) of the first course of chemotherapy predicted subsequent outcome in patients who presented with CG abnormalities. Design and Methods. D21 CG analysis was performed in 197 patients. Results. Nineteen percent of the patients had exclusively abnormal metaphases (AA), 31{\%} had only normal metaphases (NN), 39{\%} had normal and abnormal metaphases (AN), and 11{\%} had insufficient metaphases (0/0) on D21. A complete response was achieved in 79{\%} of patients with NN, 60{\%} with AN, 27{\%} of those with AA, and 32{\%} of those with 0/0. Interpretations and Conclusions. Disease-free survival in CR was longest in patients who had ≥1 normal metaphase on D21, with this finding being independent of D21 marrow and initial CG results. D21 CG can be used in therapeutic decision-making.",
keywords = "AML, Day 21 cytogenetics",
author = "Marina Konopleva and Cheng, {Su Chun} and Cortes, {Jorge E.} and Hayes, {Kimberly J.} and Pierce, {Sherry A.} and Michael Andreeff and Giles, {Francis J.} and Susan O'Brien and Kantarjian, {Hagop M.} and Estey, {Elihu H.}",
year = "2003",
month = "7",
day = "1",
language = "English (US)",
volume = "88",
pages = "733--736",
journal = "Haematologica",
issn = "0390-6078",
publisher = "Ferrata Storti Foundation",
number = "7",

}

TY - JOUR

T1 - Independent prognostic significance of day 21 cytogenetic findings in newly-diagnosed acute myeloid leukemia or refractory anemia with excess blasts

AU - Konopleva, Marina

AU - Cheng, Su Chun

AU - Cortes, Jorge E.

AU - Hayes, Kimberly J.

AU - Pierce, Sherry A.

AU - Andreeff, Michael

AU - Giles, Francis J.

AU - O'Brien, Susan

AU - Kantarjian, Hagop M.

AU - Estey, Elihu H.

PY - 2003/7/1

Y1 - 2003/7/1

N2 - Background and Objectives. We investigated whether cytogenetic findings (CG) on day 21 (D21) of the first course of chemotherapy predicted subsequent outcome in patients who presented with CG abnormalities. Design and Methods. D21 CG analysis was performed in 197 patients. Results. Nineteen percent of the patients had exclusively abnormal metaphases (AA), 31% had only normal metaphases (NN), 39% had normal and abnormal metaphases (AN), and 11% had insufficient metaphases (0/0) on D21. A complete response was achieved in 79% of patients with NN, 60% with AN, 27% of those with AA, and 32% of those with 0/0. Interpretations and Conclusions. Disease-free survival in CR was longest in patients who had ≥1 normal metaphase on D21, with this finding being independent of D21 marrow and initial CG results. D21 CG can be used in therapeutic decision-making.

AB - Background and Objectives. We investigated whether cytogenetic findings (CG) on day 21 (D21) of the first course of chemotherapy predicted subsequent outcome in patients who presented with CG abnormalities. Design and Methods. D21 CG analysis was performed in 197 patients. Results. Nineteen percent of the patients had exclusively abnormal metaphases (AA), 31% had only normal metaphases (NN), 39% had normal and abnormal metaphases (AN), and 11% had insufficient metaphases (0/0) on D21. A complete response was achieved in 79% of patients with NN, 60% with AN, 27% of those with AA, and 32% of those with 0/0. Interpretations and Conclusions. Disease-free survival in CR was longest in patients who had ≥1 normal metaphase on D21, with this finding being independent of D21 marrow and initial CG results. D21 CG can be used in therapeutic decision-making.

KW - AML

KW - Day 21 cytogenetics

UR - http://www.scopus.com/inward/record.url?scp=0038038463&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038038463&partnerID=8YFLogxK

M3 - Article

C2 - 12857550

AN - SCOPUS:0038038463

VL - 88

SP - 733

EP - 736

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 7

ER -